Panagiotis's team showed that combination therapy with a proteasome inhibitor (bortezomib) and TMZ could increase the death rate of U87 glioma cells compared with that induced by monotherapy.28 Egger et al29 reported a combination therapy of adenovirus (Ad‐FKHRL1/TM) and TMZ, which resulted in a greater tumor‐killing effect in vitro and in vivo than for either therapy alone. The gene discussed is FOXO3; the disease is central nervous system cancer.